Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Return on Capital Employed: 2016-2025

Historic Return on Capital Employed for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2025 value amounting to -0.25%.

  • Cartesian Therapeutics' Return on Capital Employed fell 11.00% to -0.25% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.25%, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -0.13% for FY2024, which is 39.00% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Return on Capital Employed is -0.25%, which was down 9.57% from -0.23% recorded in Q2 2025.
  • Cartesian Therapeutics' Return on Capital Employed's 5-year high stood at 0.20% during Q2 2022, with a 5-year trough of -0.63% in Q4 2023.
  • Over the past 3 years, Cartesian Therapeutics' median Return on Capital Employed value was -0.23% (recorded in 2025), while the average stood at -0.27%.
  • In the last 5 years, Cartesian Therapeutics' Return on Capital Employed soared by 99bps in 2021 and then tumbled by 74bps in 2023.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Return on Capital Employed stood at -0.05% in 2021, then rose by 15bps to 0.10% in 2022, then crashed by 73bps to -0.63% in 2023, then spiked by 53bps to -0.10% in 2024, then decreased by 11bps to -0.25% in 2025.
  • Its last three reported values are -0.25% in Q3 2025, -0.23% for Q2 2025, and -0.13% during Q1 2025.